No ASX ETF holds Monash IVF (MVF) as of 15 Oct 2026. Over the last year it fell 0.7%: on $10,000, −$68. We explain 7 big moves in that time.
About MVF
- SectorHealth Care
- IndustryHealth Care Equipment & Services
- Size$292.2m
- Held by0 ETFs
- Big moves7 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +5.8%18 Jun 2026· Contract
Monash IVF Group signed a national supply agreement with Memphasys for the Felix sperm selection system, a material commercial partnership that boosted investor sentiment.
- −5.9%20 Apr 2026· Takeover / M&A
Monash IVF rejected a revised takeover proposal from Genesis Capital, which the market viewed negatively.
- +15.8%13 Apr 2026· Takeover / M&A
Monash IVF received a sweetened takeover offer from a Genesis/Soul Patts consortium at 90c per share, driving the stock up 15.79%.
- −10.4%24 Dec 2025· Unknown
No direct evidence found; likely driven by sector-wide selling pressure or company-specific news not captured in article snippet.
- +44.3%24 Nov 2025· Takeover / M&A
Monash IVF rejected a $300 million takeover bid from Genesis Capital, which was considered too low.
- +5.1%20 Nov 2025· Unknown
News article reports Monash IVF's market share and patient numbers declined following embryo mix-ups, which is negative and inconsistent with the stock's upward price move.
- −5.5%13 Nov 2025· Management
Monash IVF announced a new Managing Director appointment to address company challenges, which likely triggered a negative investor reaction.
Held by 0 ETFs
No ETF we track holds MVF directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did MVF fall 5.5% on 13 Nov 2025?
Monash IVF
Monash IVF announced a new Managing Director appointment to address company challenges, which likely triggered a negative investor reaction.
The primary news near the event date is the naming of a new Managing Director 'to help right the ship,' suggesting the company has been underperforming. The price drop and high volume coincide with this announcement, making it the most plausible driver. However, the exact details of the management change and market sentiment are not fully clear from the provided articles.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage